Stoke Therapeutics, Inc. STOK Total Non-Current Liabilities
Total Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesNoncurrent.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s total non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s total non-current liabilities?
- Stoke Therapeutics, Inc. (STOK) reported total non-current liabilities of $7.59M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s total non-current liabilities changed year-over-year?
- Stoke Therapeutics, Inc.'s total non-current liabilities decreased by 37.4% year-over-year, from $12.13M to $7.59M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s total non-current liabilities?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s total non-current liabilities has grown at a 80.6% compound annual growth rate (CAGR), from $422K to $8.1M.
- What does total non-current liabilities mean?
- The sum of all long-term obligations due beyond one year — long-term debt, lease liabilities, pension obligations, and deferred items.